Roche: 100-million CHF investment in network research

8 years ago - Published in Finance, Fundamental Analysis

Roche will launch a CHF 100 million ($100.1 million) global network of 21 academic centers focused on cancer immunotherapy R&D, as the it reported in the statement today.

This network, imCORE, brings together many of the world’s leading scientific and clinical experts in cancer immunotherapy to collaborate in investigating the most promising new treatment approaches.

In addition to new treatments, imCORE will work with Roche to develop diagnostic technologies and gather and apply emerging data, Roche said.

By exploring new ways to activate a person’s immune system to fight cancer, Roche reasons, imCORE can identifying new approaches that expand the number of people who benefit from cancer immunotherapy.

“We believe the fastest way to advance progress against cancer is through collaboration, and consistent with our values, the goal of imCORE is to facilitate access to new technologies and emerging data among the top researchers around the world,” Roche CMO Dr Sandra Horning said in a statement.